Influenza, Respiratory Tract Disease, Respiratory Tract Infections, RNA Virus Infections, Virus Diseases
Conditions
Keywords
Influenza, Human, RNA Virus Infections, Lot Consistency, Immunologic, Orthomyxoviridae Infections, Infection, Virus Diseases, Vaccine, Safety, Plant-made, Virus-like particle, Hemagglutinin
Brief summary
This Phase 3 study is intended to assess the clinical lot-to-lot consistency in manufacturing by evaluating and comparing the immunogenicity of three consecutively manufactured lots of the Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine, during the 2016-2017 influenza season, in healthy adults 18-49 years of age. A single dose of one of three consecutive lots of Quadrivalent VLP Influenza Vaccine (30 µg/strain) will be administered to 1,200 participants.
Detailed description
This randomized, observer-blind, multicenter, Phase 3 lot consistency study will be conducted at multiple sites in Canada. The composition of the Quadrivalent VLP Influenza Vaccine used in this study includes two influenza A virus strains and two influenza B virus strains based on the 2016-2017 recommended strains for vaccination in the Northern hemisphere. 1,200 healthy male and female participants aged 18 to 49 years will be randomized in a 1:1:1 ratio to one of three lots of the Quadrivalent VLP Influenza Vaccine (30 μg/strain). Participant will participate in this study for approximately 21 days, during which a first visit will be scheduled on Day 0 for screening, eligibility assessment, and vaccine administration; and on Day 21 for blood sample collection for immunogenicity assessment.
Interventions
BIOLOGICALQuadrivalent VLP Influenza Vaccine
Single dose of 30 µg/strain Quadrivalent VLP Influenza Vaccine
Sponsors
Medicago
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Observer-blind
Eligibility
Sex/Gender
ALL
Age
18 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
Participants must meet all of the following inclusion criteria to be eligible for participation in this study; no protocol waivers are allowed: 1. Participants must be considered by the Investigator to be reliable and likely to cooperate with the assessment procedures and be available for the duration of the study; 2. Participants have a body mass index (BMI) ≤ 40.0 kg/m\^2 on Day 0 (pre-vaccination); 3. Participants must be in good general health prior to study participation with no clinically relevant abnormalities that could jeopardize participant safety or interfere with study assessments as assessed by the Principal Investigator or sub-Investigator (thereafter referred as Investigator) and determined by medical history, physical examination, and vital signs; Note: Participants with a pre-existing chronic disease will be allowed to participate if the disease is stable and, according to the Investigator's judgment, the condition is unlikely to confound the results of the study or pose additional risk to the participant by participating in the study. Stable disease is generally defined as no new onset or exacerbation of pre-existing chronic disease six months prior to vaccination. Based on the Investigator's judgment, a participant with a more recent stabilization of a disease could also be eligible. 4. Female participants must have a negative urine pregnancy test result at the Screening/Vaccination visit (Visit 1); 5. Female participants of childbearing potential must use an effective method of contraception for one month prior to vaccination and agree to continue employing adequate birth control measures for the duration of the study. Abstinent participants should be asked what method(s) they would use, should their circumstances change, and participants without a well-defined plan should be excluded. The following relationship or methods of contraception are considered to be effective: * Hormonal contraceptives (e.g. oral, injectable, topical \[patch\], or estrogenic vaginal ring); * Intra-uterine device with or without hormonal release; * Male partner using a condom plus spermicide or a sterilized partner (at least one year prior to vaccination); * Credible self-reported history of heterosexual vaginal intercourse abstinence until at least the Day 21 visit; * Female partner. 6. Non-childbearing females are defined as: * Surgically-sterile (defined as bilateral tubal ligation, hysterectomy, or bilateral oophorectomy performed more than one month prior to vaccination); or * Post-menopausal (absence of menses for 24 consecutive months and age consistent with natural cessation of ovulation).
Exclusion criteria
Participants who meet any of the following criteria will be excluded from participating in this study; no protocol waivers are allowed: 1. According to the Investigator's opinion, history of significant acute or chronic, uncontrolled medical or neuropsychiatric illness. 'Uncontrolled' is defined as: * Requiring a new medical or surgical treatment during the six months prior to study vaccine administration unless the criteria outlined in inclusion criterion no. 3 can be met (i.e. the Investigator can justify inclusion based upon the innocuous nature of medical/surgical events and/or treatments); * Requiring any significant change in a chronic medication (i.e. drug, dose, frequency) during the three months prior to study vaccine administration due to uncontrolled symptoms or drug toxicity, unless the innocuous nature of the medication change meets the criteria outlined in inclusion criterion no. 5 and is appropriately justified by the Investigator. 2. Any medical or neuropsychiatric condition or any history of excessive alcohol use or drug abuse which, in the Investigator's opinion, would render the participant unable to provide informed consent or unable to provide valid safety observations and reporting; 3. Any autoimmune disease other than hypothyroidism with stable replacement therapy; or any confirmed or suspected immunosuppressive condition or immunodeficiency including known or suspected human immunodeficiency virus (HIV), hepatitis B or C infection, or the presence of lymphoproliferative disease; 4. Administration or planned administration of any non-influenza vaccine within 30 days prior to randomization and up to blood sampling on Day 21. Immunization on an emergency basis will be evaluated case-by-case by the Investigator; 5. Administration of any adjuvanted or investigational influenza vaccine within 24 months prior to randomization or planned administration prior to the completion of Day 21; 6. Administration of any standard, non-adjuvanted influenza vaccine (e.g. live attenuated trivalent/quadrivalent inactivated influenza vaccine intranasal or split trivalent/quadrivalent inactivated influenza vaccine by either intradermal or IM route) within 24 months prior to randomization and up to completion of the Day 21 visit; 7. Use of any investigational or non-registered product within 30 days prior to randomization or planned use during the study period. Participants may not participate in any other investigational or marketed drug study while participating in this study until the Day 21 visit. Participation in observational studies is permitted; 8. Treatment with systemic glucocorticoids at a dose exceeding 10 milligrams (mg) of prednisone (or the equivalent) per day for more than seven consecutive days or for ten or more days in total, within one month of study vaccine administration; or any other cytotoxic or immunosuppressant drug, or any immunoglobulin preparation within three months of vaccination and until the completion of the Day 21 visit. Low doses of nasal or inhaled glucocorticoids and topical steroids are permitted; 9. Any significant disorder of coagulation including, but not limited to, treatment with warfarin derivatives or heparin. Persons receiving prophylactic anti-platelet medications (e.g. low-dose aspirin \[no more than 325 mg/day\]) and without a clinically apparent bleeding tendency are eligible. Participants treated with new generation drugs that do not increase the risk of IM bleeding (e.g. clopidogrel) are also eligible. 10. History of allergy to any of the constituents of the Quadrivalent VLP Influenza Vaccine or a tobacco allergy; 11. History of anaphylactic allergic reactions to plants or plants components; 12. Any history of serious asthma (e.g. status asthmaticus, hospitalization for asthma control) in the last three years; 13. Use of antihistamines 48 hours prior to study vaccination; 14. The use of prophylactic medications (e.g. acetaminophen/paracetamol, aspirin, naproxen, or ibuprofen) within 24 hours of randomization to prevent or pre-empt symptoms due to vaccination. Participant discovered to have taken a prophylactic medication to prevent or pre empt symptoms due to vaccination within the 24 hours prior to planned randomization must be delayed until at least the 24-hour period is met; 15. Participants who have a dermatological condition at the injection site that may interfere with injection site reaction rating; 16. Participant who have received a blood transfusion within 90 days prior to study vaccination; 17. Any female participant who has a positive or doubtful pregnancy test result prior to vaccination or who is lactating; 18. Presence of any febrile illness (including oral temperature (OT) ≥ 38.0 ˚C within 24 hours prior to vaccination). Such participants may be re-evaluated for enrolment after resolution of illness; 19. Cancer or treatment for cancer within three years of study vaccine administration. Participants with a history of cancer who are disease-free without treatment for three years or more are eligible. Individuals with treated and uncomplicated basal cell carcinoma of the skin or with non-treated, non-disseminated local prostate cancer are eligible; 20. Participants identified as an Investigator or employee of the Investigator or clinical site with direct involvement in the proposed study, or identified as an immediate family member (i.e. parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study or any employee of Medicago. Immediate family members of the Investigator or employees of a clinical site can participate in the study at another clinical site, as long as the Investigator or employees are not involved in the study at that site; 21. Participant with a history of Guillain-Barré syndrome.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain | Day 21 (post-vaccination) | The GMTs were measured using a HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage). Lot-to-lot consistency was based on adjusted GMT ratio for pairwise comparisons of the lots (Lot 1 / Lot 2, Lot 1 / Lot 3, and Lot 2 / Lot 3). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | Day 0 (pre-vaccination), Day 21 | The SP rate is the percentage of participants attaining a reciprocal HI titer of ≥ 40 on Day 21 (the percentage of vaccine recipients with a serum HI titer of at least 1:40 following vaccination). SP rate was measured using an HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage). |
| Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain | Day 0 (pre-vaccination), Day 21 | GMFR, the geometric mean of the ratio of GMTs (Day 21/Day 0), was measured using an HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage). |
| Number of Participants With at Least One Immediate Complaint | 15 minutes post-vaccination | Immediate complaints were defined as any solicited local or systemic reactions. Solicited local reactions included: erythema, swelling, and pain at the injection site and solicited systemic reactions included: fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, and swelling in the neck. |
| Number of Participants With at Least One Solicited Local and/or Systemic Reactions | Day 0 (post-vaccination) up to Day 7 | Participants were monitored for both solicited local reactions (erythema, swelling, and pain at the injection site) and solicited systemic reactions (fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, and swelling in the neck). Any solicited local or systemic immediate complaint was also included. |
| Number of Participants With ≥ Severe Solicited Local and Systemic Reaction | Day 0 (post-vaccination) up to Day 7 | Participants were monitored for both solicited local reactions (erythema, swelling, pain at the injection site) and solicited systemic reactions (fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, swelling in the neck). Any solicited local or systemic immediate complaint was also included. Intensity of solicited reactions graded as mild (1)-easily tolerated and does not interfere with usual activity; moderate (2)-interferes with daily activity, but the participant is still able to function; severe (3)-incapacitating and the participant is unable to work or complete usual activity or potentially life threatening;(4)-likely to be life-threatening if not treated in a timely manner, according to the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. The ≥severe events included severe and potentially life-threatening events. |
| Number of Participants With ≥ Severe Related Solicited Local and Systemic Reactions | Day 0 (post-vaccination) up to Day 7 | Participants were monitored for both solicited local reactions (erythema, swelling, pain at the injection site) and solicited systemic reactions (fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, swelling in the neck). Intensity of solicited reactions was graded according to the FDA toxicity grade: mild (1); moderate (2); severe (3); (4)-likely to be life-threatening if not treated in a timely manner. Causal relationship with study vaccine was assessed as definitely not related (clearly not related),probably not related (no medical evidence),possibly related(reasonable possibility of cause and effect),probably related(plausible biologic mechanism and temporal relationship) or definitely related(direct cause and effect relationship). The ≥severe events included severe and potentially life-threatening and the related category included possibly related, probably related, and definitely related. |
| Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain | Day 0 (pre-vaccination) to Day 21 | The SC rate is the percentage of participants with either a ≥ 4-fold increase in reciprocal HI titers between Day 0 and Day 21 or a rise of undetectable HI titer (i.e. \<10) pre-vaccination (Day 0) to an HI titer of ≥40 on Day 21 post-vaccination. SC rate was measured using an HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage). |
| Number of Participants With ≥ Severe Unsolicited TEAEs | Day 0 (post-vaccination) up to Day 21 | The intensity of the unsolicited TEAEs was graded as mild (1)-easily tolerated and does not interfere with usual activity; moderate (2)-interferes with daily activity, but the participant is still able to function; severe (3)-incapacitating and the participant is unable to work or complete usual activity or potentially life threatening; (4)-likely to be life-threatening if not treated in a timely manner, according to the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. The ≥ Severe events included severe and potentially life-threatening events. AE and TEAEs are defined in outcome measure#9. |
| Number of Participants With ≥ Severe Related Unsolicited TEAEs | Day 0 (post-vaccination) up to Day 21 | The intensity of the unsolicited TEAEs was graded as: mild (1), moderate (2), severe (3) or potentially life threatening (4). The causal relationship with the study vaccine was assessed as definitely not related (clearly not related),probably not related (no medical evidence), possibly related (reasonable possibility of cause and effect), probably related (plausible biologic mechanism and temporal relationship) or definitely related (direct cause and effect relationship). The ≥severe events included severe and potentially life-threatening and the related category included possibly related, probably related, and definitely related. AE and TEAEs are defined in outcome measure #9. |
| Number of Participants With an Occurrence of Death | Day 0 (post-vaccination) up to Day 21 | The number of participants with an occurrence of death was assessed. |
| Number of Participants With at Least One Serious TEAE | Day 0 (post-vaccination) up to Day 21 | A serious adverse event (SAE) was considered to be any untoward medical occurrence (whether or not considered to be related to the study vaccine) that, at any dose results in death; is life-threatening (at the time of the event); requires inpatient hospitalization (≥ 24 hours) or prolongation of existing hospitalization (elective hospitalizations/procedures for pre-existing conditions that have not worsened are excluded); results in persistent or significant disability/incapacity; is a congenital abnormality/birth defect; or is another medically important event (e.g. any cases of newly diagnosed cancer). AE and TEAEs is defined in outcome measure #9. |
| Number of Participants With at Least One AE Leading to Withdrawal | Day 0 (post-vaccination) up to Day 21 | An AE or adverse experience was defined as any untoward medical occurrence in a participant or clinical investigation participant who was administered a pharmaceutical product, with or without a causal relationship with the treatment. An AE can be any favorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to a medicinal product. The number of participants with at least one adverse event leading to withdrawal was assessed. |
| Number of Participants With at Least One New Onset Chronic Diseases (NOCDs) | Day 0 (post-vaccination) up to Day 21 | All NOCDs that may plausibly have an allergic, autoimmune or inflammatory component were reported. Plausibility should be interpreted broadly; however, the only clear exceptions are degenerative conditions such as osteoarthritis, age-related physiologic changes and life-style diseases. In this context, most cancers, cardiac conditions and kidney diseases should be reported. NOCDs were collected from vaccination on Day 0 to the end of the Day 21 visit. |
| Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs) | Day 0 (post-vaccination) up to Day 21 | Participants were monitored for unsolicited TEAEs. An adverse event (AE) or adverse experience was defined as any untoward medical occurrence in a participant or clinical investigation participant who was administered a pharmaceutical product, with or without a causal relationship with the treatment. An AE can be any favorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to a medicinal product. An AE was considered treatment-emergent if it was aggravated in severity or frequency following the administration of the study vaccine, up to and including the last visit of the study. |
Countries
Canada
Participant flow
Recruitment details
Participants were randomized in a 1:1:1 ratio to receive one of the three lots of the Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine at a dose of 30 μg/strain.
Pre-assignment details
Participants were healthy adults 18 to 49 years of age assessed during the 2016-2017 influenza season.
Participants by arm
| Arm | Count |
|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0. | 401 |
| Quadrivalent VLP Influenza Vaccine - Lot 2 Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0. | 398 |
| Quadrivalent VLP Influenza Vaccine - Lot 3 Participants received one IM injection of 0.5 mL of their assigned vaccine lot of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0. | 401 |
| Total | 1,200 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 2 | 0 | 1 |
| Overall Study | Other than specified | 0 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 2 | 1 |
Baseline characteristics
| Characteristic | Quadrivalent VLP Influenza Vaccine - Lot 1 | Quadrivalent VLP Influenza Vaccine - Lot 2 | Quadrivalent VLP Influenza Vaccine - Lot 3 | Total |
|---|---|---|---|---|
| Age, Continuous | 30.5 years STANDARD_DEVIATION 9.31 | 29.9 years STANDARD_DEVIATION 8.9 | 29.4 years STANDARD_DEVIATION 8.8 | 29.9 years STANDARD_DEVIATION 9.01 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 21 Participants | 20 Participants | 27 Participants | 68 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 380 Participants | 377 Participants | 374 Participants | 1131 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 63 Participants | 66 Participants | 58 Participants | 187 Participants |
| Race (NIH/OMB) Black or African American | 17 Participants | 24 Participants | 28 Participants | 69 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 1 Participants | 3 Participants | 6 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 318 Participants | 305 Participants | 310 Participants | 933 Participants |
| Sex: Female, Male Female | 216 Participants | 224 Participants | 217 Participants | 657 Participants |
| Sex: Female, Male Male | 185 Participants | 174 Participants | 184 Participants | 543 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 401 | 0 / 398 | 0 / 401 |
| other Total, other adverse events | 94 / 401 | 92 / 398 | 95 / 401 |
| serious Total, serious adverse events | 0 / 401 | 1 / 398 | 0 / 401 |
Outcome results
Primary
Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain
The GMTs were measured using a HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage). Lot-to-lot consistency was based on adjusted GMT ratio for pairwise comparisons of the lots (Lot 1 / Lot 2, Lot 1 / Lot 3, and Lot 2 / Lot 3).
Time frame: Day 21 (post-vaccination)
Population: The Per Protocol (PP) analysis set consisted of the participants with no major deviations related to the analyses and with Day 0 and Day 21 immunogenicity assessments.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain | A/H3N2 (Hong Kong) | 96.3 titers |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain | A/H1N1 (California) | 603.7 titers |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain | B/Brisbane | 41.8 titers |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain | B/Phuket | 215.7 titers |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain | B/Phuket | 231.1 titers |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain | A/H3N2 (Hong Kong) | 103.0 titers |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain | A/H1N1 (California) | 595.6 titers |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain | B/Brisbane | 41.9 titers |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain | A/H1N1 (California) | 630.6 titers |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain | B/Phuket | 235.9 titers |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain | B/Brisbane | 38.3 titers |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain | A/H3N2 (Hong Kong) | 88.0 titers |
Comparison: A/H1N1 (California)95% CI: [0.87, 1.18]
Comparison: A/H1N1 (California)95% CI: [0.82, 1.12]
Comparison: A/H1N1 (California)95% CI: [0.81, 1.1]
Comparison: A/H3N2 (Hong Kong)95% CI: [0.77, 1.13]
Comparison: A/H3N2 (Hong Kong)95% CI: [0.91, 1.32]
Comparison: A/H3N2 (Hong Kong)95% CI: [0.97, 1.41]
Comparison: B/Brisbane95% CI: [0.87, 1.15]
Comparison: B/Brisbane95% CI: [0.95, 1.26]
Comparison: B/Brisbane95% CI: [0.95, 1.26]
Comparison: B/Phuket95% CI: [0.8, 1.09]
Comparison: B/Phuket95% CI: [0.78, 1.07]
Comparison: B/Phuket95% CI: [0.84, 1.15]
Secondary
Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain
GMFR, the geometric mean of the ratio of GMTs (Day 21/Day 0), was measured using an HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage).
Time frame: Day 0 (pre-vaccination), Day 21
Population: PP Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain | A/H3N2 (Hong Kong) | 8.41 ratio |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain | B/Phuket | 5.76 ratio |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain | B/Brisbane | 4.08 ratio |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain | A/H1N1 (California) | 8.55 ratio |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain | A/H3N2 (Hong Kong) | 8.99 ratio |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain | A/H1N1 (California) | 8.43 ratio |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain | B/Phuket | 6.17 ratio |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain | B/Brisbane | 4.09 ratio |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain | B/Phuket | 6.30 ratio |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain | B/Brisbane | 3.73 ratio |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain | A/H1N1 (California) | 8.93 ratio |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Geometric Mean of the Ratio of GMTs (Geometric Mean Fold Rise [GMFR]) of HI Antibody Response for Each Homologous Influenza Strain | A/H3N2 (Hong Kong) | 7.69 ratio |
Secondary
Number of Participants With an Occurrence of Death
The number of participants with an occurrence of death was assessed.
Time frame: Day 0 (post-vaccination) up to Day 21
Population: SAS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Number of Participants With an Occurrence of Death | 0 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Number of Participants With an Occurrence of Death | 0 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Number of Participants With an Occurrence of Death | 0 Participants |
Secondary
Number of Participants With at Least One AE Leading to Withdrawal
An AE or adverse experience was defined as any untoward medical occurrence in a participant or clinical investigation participant who was administered a pharmaceutical product, with or without a causal relationship with the treatment. An AE can be any favorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to a medicinal product. The number of participants with at least one adverse event leading to withdrawal was assessed.
Time frame: Day 0 (post-vaccination) up to Day 21
Population: SAS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Number of Participants With at Least One AE Leading to Withdrawal | 0 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Number of Participants With at Least One AE Leading to Withdrawal | 0 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Number of Participants With at Least One AE Leading to Withdrawal | 0 Participants |
Secondary
Number of Participants With at Least One Immediate Complaint
Immediate complaints were defined as any solicited local or systemic reactions. Solicited local reactions included: erythema, swelling, and pain at the injection site and solicited systemic reactions included: fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, and swelling in the neck.
Time frame: 15 minutes post-vaccination
Population: SAS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Number of Participants With at Least One Immediate Complaint | 96 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Number of Participants With at Least One Immediate Complaint | 108 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Number of Participants With at Least One Immediate Complaint | 106 Participants |
Secondary
Number of Participants With at Least One New Onset Chronic Diseases (NOCDs)
All NOCDs that may plausibly have an allergic, autoimmune or inflammatory component were reported. Plausibility should be interpreted broadly; however, the only clear exceptions are degenerative conditions such as osteoarthritis, age-related physiologic changes and life-style diseases. In this context, most cancers, cardiac conditions and kidney diseases should be reported. NOCDs were collected from vaccination on Day 0 to the end of the Day 21 visit.
Time frame: Day 0 (post-vaccination) up to Day 21
Population: SAS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Number of Participants With at Least One New Onset Chronic Diseases (NOCDs) | 0 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Number of Participants With at Least One New Onset Chronic Diseases (NOCDs) | 0 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Number of Participants With at Least One New Onset Chronic Diseases (NOCDs) | 0 Participants |
Secondary
Number of Participants With at Least One Serious TEAE
A serious adverse event (SAE) was considered to be any untoward medical occurrence (whether or not considered to be related to the study vaccine) that, at any dose results in death; is life-threatening (at the time of the event); requires inpatient hospitalization (≥ 24 hours) or prolongation of existing hospitalization (elective hospitalizations/procedures for pre-existing conditions that have not worsened are excluded); results in persistent or significant disability/incapacity; is a congenital abnormality/birth defect; or is another medically important event (e.g. any cases of newly diagnosed cancer). AE and TEAEs is defined in outcome measure #9.
Time frame: Day 0 (post-vaccination) up to Day 21
Population: SAS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Number of Participants With at Least One Serious TEAE | 0 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Number of Participants With at Least One Serious TEAE | 1 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Number of Participants With at Least One Serious TEAE | 0 Participants |
Secondary
Number of Participants With at Least One Solicited Local and/or Systemic Reactions
Participants were monitored for both solicited local reactions (erythema, swelling, and pain at the injection site) and solicited systemic reactions (fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, and swelling in the neck). Any solicited local or systemic immediate complaint was also included.
Time frame: Day 0 (post-vaccination) up to Day 7
Population: SAS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Number of Participants With at Least One Solicited Local and/or Systemic Reactions | 314 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Number of Participants With at Least One Solicited Local and/or Systemic Reactions | 321 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Number of Participants With at Least One Solicited Local and/or Systemic Reactions | 321 Participants |
Secondary
Number of Participants With ≥ Severe Related Solicited Local and Systemic Reactions
Participants were monitored for both solicited local reactions (erythema, swelling, pain at the injection site) and solicited systemic reactions (fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, swelling in the neck). Intensity of solicited reactions was graded according to the FDA toxicity grade: mild (1); moderate (2); severe (3); (4)-likely to be life-threatening if not treated in a timely manner. Causal relationship with study vaccine was assessed as definitely not related (clearly not related),probably not related (no medical evidence),possibly related(reasonable possibility of cause and effect),probably related(plausible biologic mechanism and temporal relationship) or definitely related(direct cause and effect relationship). The ≥severe events included severe and potentially life-threatening and the related category included possibly related, probably related, and definitely related.
Time frame: Day 0 (post-vaccination) up to Day 7
Population: SAS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Number of Participants With ≥ Severe Related Solicited Local and Systemic Reactions | 3 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Number of Participants With ≥ Severe Related Solicited Local and Systemic Reactions | 8 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Number of Participants With ≥ Severe Related Solicited Local and Systemic Reactions | 3 Participants |
Secondary
Number of Participants With ≥ Severe Related Unsolicited TEAEs
The intensity of the unsolicited TEAEs was graded as: mild (1), moderate (2), severe (3) or potentially life threatening (4). The causal relationship with the study vaccine was assessed as definitely not related (clearly not related),probably not related (no medical evidence), possibly related (reasonable possibility of cause and effect), probably related (plausible biologic mechanism and temporal relationship) or definitely related (direct cause and effect relationship). The ≥severe events included severe and potentially life-threatening and the related category included possibly related, probably related, and definitely related. AE and TEAEs are defined in outcome measure #9.
Time frame: Day 0 (post-vaccination) up to Day 21
Population: SAS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Number of Participants With ≥ Severe Related Unsolicited TEAEs | 2 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Number of Participants With ≥ Severe Related Unsolicited TEAEs | 0 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Number of Participants With ≥ Severe Related Unsolicited TEAEs | 0 Participants |
Secondary
Number of Participants With ≥ Severe Solicited Local and Systemic Reaction
Participants were monitored for both solicited local reactions (erythema, swelling, pain at the injection site) and solicited systemic reactions (fever, headache, fatigue, muscle aches, joint aches, chills, a feeling of general discomfort, swelling in the axilla, swelling in the neck). Any solicited local or systemic immediate complaint was also included. Intensity of solicited reactions graded as mild (1)-easily tolerated and does not interfere with usual activity; moderate (2)-interferes with daily activity, but the participant is still able to function; severe (3)-incapacitating and the participant is unable to work or complete usual activity or potentially life threatening;(4)-likely to be life-threatening if not treated in a timely manner, according to the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. The ≥severe events included severe and potentially life-threatening events.
Time frame: Day 0 (post-vaccination) up to Day 7
Population: SAS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Number of Participants With ≥ Severe Solicited Local and Systemic Reaction | 5 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Number of Participants With ≥ Severe Solicited Local and Systemic Reaction | 11 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Number of Participants With ≥ Severe Solicited Local and Systemic Reaction | 6 Participants |
Secondary
Number of Participants With ≥ Severe Unsolicited TEAEs
The intensity of the unsolicited TEAEs was graded as mild (1)-easily tolerated and does not interfere with usual activity; moderate (2)-interferes with daily activity, but the participant is still able to function; severe (3)-incapacitating and the participant is unable to work or complete usual activity or potentially life threatening; (4)-likely to be life-threatening if not treated in a timely manner, according to the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. The ≥ Severe events included severe and potentially life-threatening events. AE and TEAEs are defined in outcome measure#9.
Time frame: Day 0 (post-vaccination) up to Day 21
Population: SAS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Number of Participants With ≥ Severe Unsolicited TEAEs | 4 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Number of Participants With ≥ Severe Unsolicited TEAEs | 3 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Number of Participants With ≥ Severe Unsolicited TEAEs | 2 Participants |
Secondary
Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs)
Participants were monitored for unsolicited TEAEs. An adverse event (AE) or adverse experience was defined as any untoward medical occurrence in a participant or clinical investigation participant who was administered a pharmaceutical product, with or without a causal relationship with the treatment. An AE can be any favorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to a medicinal product. An AE was considered treatment-emergent if it was aggravated in severity or frequency following the administration of the study vaccine, up to and including the last visit of the study.
Time frame: Day 0 (post-vaccination) up to Day 21
Population: SAS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs) | 94 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs) | 92 Participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs) | 95 Participants |
Secondary
Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain
The SC rate is the percentage of participants with either a ≥ 4-fold increase in reciprocal HI titers between Day 0 and Day 21 or a rise of undetectable HI titer (i.e. \<10) pre-vaccination (Day 0) to an HI titer of ≥40 on Day 21 post-vaccination. SC rate was measured using an HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage).
Time frame: Day 0 (pre-vaccination) to Day 21
Population: PP Set.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain | A/H1N1 (California) | 73.3 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain | A/H3N2 (Hong Kong) | 60.9 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain | B/Brisbane | 41.2 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain | B/Phuket | 63.2 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain | B/Phuket | 55.4 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain | A/H1N1 (California) | 68.7 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain | B/Brisbane | 42.8 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain | A/H3N2 (Hong Kong) | 63.2 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain | B/Phuket | 61.2 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain | A/H3N2 (Hong Kong) | 57.4 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain | B/Brisbane | 39.0 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Percentage of Participants With Seroconversion (SC) Measured by HI Antibody Response for Each Homologous Influenza Strain | A/H1N1 (California) | 73.1 percentage of participants |
Secondary
Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain
The SP rate is the percentage of participants attaining a reciprocal HI titer of ≥ 40 on Day 21 (the percentage of vaccine recipients with a serum HI titer of at least 1:40 following vaccination). SP rate was measured using an HI assay for the homologous strains: A/California/7/2009 (H1N1), A/Hong Kong/4801/2014 (H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage).
Time frame: Day 0 (pre-vaccination), Day 21
Population: PP Set.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | A/H1N1 (California): Day 0 | 72.3 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | B/Brisbane: Day 21 | 60.1 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | A/H1N1 (California): Day 21 | 96.1 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | B/Brisbane: Day 0 | 13.5 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | A/H3N2 (Hong Kong): Day 21 | 80.3 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | A/H3N2 (Hong Kong): Day 0 | 20.0 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | B/Phuket: Day 21 | 90.7 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 1 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | B/Phuket: Day 0 | 51.6 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | A/H3N2 (Hong Kong): Day 0 | 19.8 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | A/H3N2 (Hong Kong): Day 21 | 79.6 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | B/Brisbane: Day 0 | 12.3 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | B/Brisbane: Day 21 | 59.8 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | A/H1N1 (California): Day 0 | 76.5 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | A/H1N1 (California): Day 21 | 97.1 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | B/Phuket: Day 0 | 58.8 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 2 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | B/Phuket: Day 21 | 92.4 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | B/Brisbane: Day 0 | 13.4 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | A/H1N1 (California): Day 0 | 76.7 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | B/Phuket: Day 21 | 93.8 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | A/H3N2 (Hong Kong): Day 0 | 18.4 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | B/Phuket: Day 0 | 57.9 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | B/Brisbane: Day 21 | 55.8 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | A/H1N1 (California): Day 21 | 98.7 percentage of participants |
| Quadrivalent VLP Influenza Vaccine - Lot 3 | Percentage of Participants With Seroprotection (SP) Measured by HI Antibody Response of for Each Homologous Influenza Strain | A/H3N2 (Hong Kong): Day 21 | 77.5 percentage of participants |